- Thursday, May 27, 2010, 7:08
- Constipation
- 89
Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC). (Source: GastroIntestinal News From Medical News Today)
Go to Source Full story
- Sunday, November 29, 2009, 14:50
- Health News
- 0
Sucampo Pharma Europe, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of Sucampo Pharmaceuticals, Inc.
Go to Source Full story
- Saturday, November 21, 2009, 11:39
- Featured, Health News
- 559
Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC).
This is the first European regulatory approval for Sucampo and Amitiza is the ...
Full story